PetMed Express (NASDAQ:PETS – Get Free Report) will likely be posting its Q2 2027 results after the market closes on Tuesday, November 10th. Analysts expect PetMed Express to post earnings of ($0.11) per share and revenue of $62.00 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2027 earnings report page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:30 PM ET.
PetMed Express (NASDAQ:PETS – Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.40). PetMed Express had a negative net margin of 17.34% and a negative return on equity of 91.69%. The company had revenue of $41.02 million for the quarter, compared to the consensus estimate of $71.00 million. On average, analysts expect PetMed Express to post ($0.50) EPS for the current fiscal year and ($0.35) EPS for the next fiscal year.
PetMed Express Price Performance
NASDAQ PETS opened at $1.22 on Friday. PetMed Express has a 1 year low of $1.15 and a 1 year high of $4.10. The firm has a market cap of $26.45 million, a price-to-earnings ratio of -0.88 and a beta of 0.82. The company has a fifty day moving average price of $1.43 and a 200-day moving average price of $2.07.
Analyst Ratings Changes
A number of research firms recently weighed in on PETS. Morgan Stanley dropped their price target on shares of PetMed Express from $2.15 to $1.40 and set an “underweight” rating on the stock in a research report on Friday, September 25th. Wall Street Zen cut shares of PetMed Express from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Zacks Research downgraded shares of PetMed Express from a “hold” rating to a “strong sell” rating in a research report on Friday, September 25th. Finally, Weiss Ratings raised shares of PetMed Express from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, October 14th. Three research analysts have rated the stock with a Sell rating. According to data from MarketBeat.com, the stock presently has an average rating of “Strong Sell” and a consensus target price of $1.40.
Read Our Latest Report on PETS
About PetMed Express
PetMed Express, Inc, doing business as PetMeds, is an online retailer of prescription and nonprescription medications and health products for dogs, cats and other household pets. The company offers products used to treat or prevent conditions such as allergies, infections, parasites and chronic illnesses, including prescription medicines, flea and tick treatments, heartworm preventatives, supplements and other animal-health products.
In addition to medications, PetMeds sells pet food, treats, vitamins, wellness products and selected supplies.
Further Reading
- Five stocks we like better than PetMed Express
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for PetMed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express and related companies with MarketBeat.com's FREE daily email newsletter.
